Multiple Myeloma Survival Rates and Life Expectancy by Hospital and Specialist
Myeloma is considered to be a rare, complex, and historically believed to be an incurable cancer. This web site provided a listing of survival rates of Multiple Myeloma Specialists. You will find you are between 1.9 and 5.7 times more likely to die in 5 years at the average SEER facility(Statistics developed by the National Cancer Institute) than if under the care of one of these exceptional myeloma professionals or under the care of a doctor considered to be a myeloma specialist. An explanation of the math is provided at the end of this home page. You will also find a more complete listing of myeloma specialists that may not have survival statistics listed here but have an excellent reputation if you click Specialists. This site also includes a Multiple Myeloma Blog with a few of the most viewed posts listed below. Just click on any of them to view the blog post.
- Multiple Myeloma - Why Do People Beat the Average Myeloma Life Expectancy Prognosis?
- Multiple Myeloma Survival Finally Improved To 5 Years! Yeah!!! And In Two More Years It Will Reach 6 Years!
- No Respect! Myeloma Patient's Don't Even Get Credit For Dying! Do The Myeloma Math.
- Why do people die from Multiple Myeloma? Lack Of Awareness?? It Is Complicated!!
- Beat the Multiple Myeloma Life Expectancy Prognosis - How to Educate Yourself!
- Does a Second Opinion from a Myeloma Specialist Improve your Life Expectancy Prognosis?? I Say YES!
Multiple Myeloma Definition - Multiple Myeloma is a blood cancer of the plasma cells(white blood cells found in the bone marrow) that requires treatment support from a skilled multiple myeloma specialist to provide you the best possible prognosis for the longest life expectancy. This site provides the most relevant multiple myeloma survival rate statistics that can be found or developed to provide multiple myeloma patients with survival rates by hospital, specialist, and region. At a recent Myeloma Cure Panel Broadcast on Cure vs. Control the panel which consisted of four long term myeloma survivors, authors, bloggers, and myeloma advocates had two universal recommendations for long term survival and improved life expectancy. For a more detailed definition of myeloma, its symptoms, and an overview of treatments just click on SITE1 or SITE2.
1. Having a multiple myeloma specialist on your team is critical to improve your life expectancy, and having one as your doctor or as a consult for second opinions provides your best chance of long term survival. You can find a multiple myeloma specialist on this site or by following some of the recommendations below or provided on the myeloma blog.
2. Given that there isn't a consensus about how to treat the disease, patients must unfortunately educate themselves about their options -- the patient must be his/her own advocate, beginning with learning about the disease and different treatment choices. It is important to get educated about Myeloma via various ways, including asking their doctors questions, taking advantage of the many excellent webinars & seminars, and sharing experiences via support groups both in person and on-line.
The SEER(Surveillance, Epidemiology and End Results) data from the National Cancer Institute provides survival data for many cancers including multiple myeloma. The 4 year survival rate reported by SEER for multiple myeloma is 57.7%, whereas the Mayo Clinic reports their 4 year survival rate at close to 90%. Dr. Hari of the Medical College of Wisconsin provided a 3 year survival rate of 93.8%* vs. the SEER data of 55.6%, the best 3 year rate yet reported on this site. Also a doctor in LA, Dr. Berenson has shown 5 year survival of 89.7%*, and this is much better than the SEER data of 41%. Therefore, you are nearly 5.7* times more likely to die in 5 years at the average SEER facility than if under Dr. Berenson's care. Another way of saying this is that for every 100 patients Dr. Berenson will have lost 10.3 patients, whereas the average SEER facility would have lost 59 patients. UAMS is an excellent center and publishes their average life expectancy of almost 9 years versus the recent SEER life expectancy of 4 years. We believe this type of information, if available, will be invaluable to all multiple myeloma patients. God bless you all who have to be on this journey! You can email us with your comments or suggestions at editor@myelomasurvival.com.
The myeloma survival rates have been obtained on line or received from myeloma specialists are as follows, and the comparison data from the National Cancer Institute or SEER(Surveillance, Epidemiology and End Results) data base is at the following link if you CLICK HERE.
The data below is getting aged, with some being 5 to 10 years of age. Because of the excellent recent myeloma treatment progress and new drugs, I would expect their experience to have improved. However, some of the doctors who had submitted data have left these facilities, so I have eliminated them from the list. Some of those facilities include Shands at the University of Florida(Dr. Moreb has moved), University of Iowa Hospitals and Clinics(Dr. Tricot has left and Iowa's listing was based on his past experience at Huntsman Cancer Institute), Mount Sinai Medical Center, NY, NY, (Dr. Barlogie has retired and Mt. Sinai's listing was based on Dr. Barlogie's UAMS past experience), University of Nebraska Medical Center, the listing was based on data submitted Dr. Edward Faber who has moved to another facility. All of these facilities are probably remain excellent, however I have no more logical support to maintain their listing.
The data below is getting aged, with some being 5 to 10 years of age. Because of the excellent recent myeloma treatment progress and new drugs, I would expect their experience to have improved. However, some of the doctors who had submitted data have left these facilities, so I have eliminated them from the list. Some of those facilities include Shands at the University of Florida(Dr. Moreb has moved), University of Iowa Hospitals and Clinics(Dr. Tricot has left and Iowa's listing was based on his past experience at Huntsman Cancer Institute), Mount Sinai Medical Center, NY, NY, (Dr. Barlogie has retired and Mt. Sinai's listing was based on Dr. Barlogie's UAMS past experience), University of Nebraska Medical Center, the listing was based on data submitted Dr. Edward Faber who has moved to another facility. All of these facilities are probably remain excellent, however I have no more logical support to maintain their listing.
Western Region
Institute for Myeloma & Bone Cancer Research(Dr.James Berenson), West Hollywood, CA - In a study of 100 of his patients his 5 year survival rate is 89.7%* vs. the SEER data of 40.9%. This is the best 5 year life expectancy yet presented on this site. This means you are 5.7* times more likely to die at the average SEER facility than at IMBCR. This is truly a remarkable accomplishment. Link: www.berensononcology.com
Seattle Cancer Care Alliance(Fred Hutchinson Cancer Research Center) , Seattle Washington - Their web site was recently updated and shows a 40% improvement within the last 5 years and now lists a 5 year survival rate of 72.7% versus the SEER data of 45.7%. They continually update survival rates and compare their performance to themselves and to their competition. Measurement and continuous improvement is a big reason they are beating the averages. You are therefore 1.9 times likely to die in the average SEER facility than in the care of SCCA. Link: http://www.seattlecca.org/diseases/myeloma-survival-rates.cfm
Southern Region
MD Anderson, Houston, TX - In a recent publication they report their 5 year overall survival for the period between 1995 to 2004. The 5 year relative survival is 60.1% vs the SEER data for this same period of 34.1%. So this means you are 1.7 times more likely to die in 5 years in the care of the average SEER facility than if under the care of MD Anderson. The results if based on data that is current, would most likely be improved over the performance listed above. Overall survival numbers for the SEER data tend to improve over time, and I would guess MD Anderson's would as well. You can find this data if you CLICK HERE and go to page 264.
UAMS(Dr. Fritz Van Rhee), Little Rock AR - The 5 year relative survival rate for newly diagnosed patients is 79.4%* vs. the SEER relative survival data of 48.4%*. This means that you are 2.5* times more likely to die under the care of the average SEER facility than if treated at UAMS Their estimate for life expectancy for newly diagnosed Total Therapy 3 and 4 patients is now 15 years, which is the longest yet reported on this site and is 3.5 times longer than the 4 year average reported by the National Cancer Institute. For the link CLICK HERE. UAMS is one of the only if not the only facility that professes to CURE for multiple myeloma in approximately 40% of their low risk patients utilizing their Total Therapy 3a protocol. A great link to a debate at UAMS between Dr. Barlogie(UAMS) and Dr. Rajkumar(Mayo) about "Cure vs. Control" can be seen if you CLICK HERE.
Midwest Region
Cleveland Clinic, Cleveland, OH - The Cleveland Clinic is a top 10 cancer hospital in the USA and publishes its yearly cancer survival rates for most cancers in its annual Cancer Outcomes document. I think this is one of the reasons they are one of the best myeloma hospitals in the country. They are continuously measuring patient outcomes and improving treatments to improve on those outcomes. The 4 year survival has recently been updated and now is 74.8% vs the SEER data of 49.1%. This is an impressive 42% improvement over their previously published information. If you are newly diagnosed you are 2.02 times more likely to die in four years if treated at the average SEER facility than if treated at the Cleveland Clinic. CLICK HERE and note page 24 on the link.
Kenwood Hospital, Oncology/Hematology Care( Dr. Edward A. Faber Jr,) Cincinnati Ohio - Dr. Faber recently moved from University of Nebraska, and believes he will duplicate his prior UNMC experience at Oncology/Hematology Care. Dr. Faber has provided their transplant experience over the past 5 years, and reported a 2 year survival rate of 93.9%* versus the SEER data of 64.1%, and a 4 year survival rate of 67.8%* versus the SEER survival rate of 49.2%. You are 5.9 times more likely to die in 2 years and 1.6 times more likely to die in 4 years if treated a the average SEER facility vs. under Dr. Faber's care. Therefore, receiving care through Dr. Faber is another excellent alternative for multiple myeloma patients in the Midwest. Since maintenance therapy with lenalidomide has only recently been adopted, Dr. Faber believes his 4 year survival statistics will continue to improve. Link: http://www.ohcare.com/physician/edward-a-faber-jr-d-o-m-s/
Mayo Clinic(Dr. Vincent Rajkumar), Rochester, MN - The Mayo Clinic published an update of their myeloma survival rates for transplant eligible and posted it on line on 12/3/2018. They reported Overall Survival (OS). OS includes death from all causes and The SEER data is based on Relative Survival which excluded non myeloma deaths. The Mayo Relative Survival rates are 95.9% at 2 years versus the SEER rate of 72% and 89.8% at 4 years versus the SEER rate of 57.7% When compared to the SEER rate you are at 6 times more likely to die in 2 years and 4.1 times more likely to die in 4 years at the average SEER facility than if you were under the care of the Mayo, Rochester. You can see a graph of the data if you CLICK HERE. This data is reflected in a OS study of 518 consecutive transplant eligible patients seen at Mayo Clinic. An outline of Mayo's risk adapted treatment template called mSmart can be found at the attached link: http://www.msmart.org/
Medical College of Wisconsin(Dr Parameswaran Hari), Milwaukee, Wisconsin - They have provided their 3 year survival of 93.8%* vs. the SEER data of 55.6%. Their 2 year survival was equally impressive at 97.7%* vs. the SEER survival rate of 65%. This is now the best 3 year survival rate for a facility yet presented on this site. This is a remarkable performance and is exactly why this site was developed. This is such a great find, for a center that is not that well known outside the Wisconsin area, and has a myeloma patient population of 1000. I think Milwaukee's little myeloma treasure is no longer their little secret. You are 13* times more likely to die in 2 years and 7.2* times more likely to die in 3 years under the care of the average SEER facility vs. under the care of Dr. Hari. For a Link CLICK HERE
The James - Ohio State University, Columbus, Ohio - They have provided graphs which show their 2 year survival of 93.3%* vs. the SEER data of 71.7%. Their 4 year survival was equally impressive at 86.8* vs. the SEER survival rate of 54.8%. Dr. Hofmeister has been integral to the development of a registry for all patients with plasma cell dyscrasia at Ohio State. They join a select group of hospitals which measure patient outcomes as a way to provide continuous improvement to their cancer care regimens. You are 4.2* times more likely to die in 2 years and 3.4* times more likely to die in 4 years under the care of the average SEER facility vs. under the care of Dr. Hofmeister. SEER survival statistics include smoldering patients and The James had a significant representation.
University of Kansas Cancer Center (Siddhartha Ganguly, MD, FACP) Kansas City, Kansas – This is a new one on me, because if we adjust the observed survival for patients under the care of Dr. Ganguly, the relative survival rate for two years is 100.1%. What this means is that in the first two years Dr. Ganguly's patients have a better chance of survival than the average American without multiple myeloma. That is a remarkable performance. Also, you are 3.3* times more likely to die in 4 years at the average SEER facility than if treated by Dr. Ganguly. They have provided their transplant experience over the past 5 years and report a 2 year survival rate of 100.1%* versus the SEER data of 64.1%, and a 4 year survival rate of 84.8%* versus the SEER survival rate of 49.2%. Therefore, receiving care through Dr. Ganguly is one of the best options for patients with multiple myeloma in the Midwest region. For the Link CLICK HERE
University of Nebraska Medical Center ,Omaha, Nebraska - They have provided their transplant experience over the past 5 years, and report a 2 year survival rate of 93.9%* versus the SEER data of 64.1%, and a 4 year survival rate of 67.8%* versus the SEER survival rate of 49.2%. You are 5.9 times more likely to die in 2 years and 1.6 times more likely to die in 4 years if treated at the average SEER facility vs. care at UNMC. Therefore, receiving care at the University of Nebraska Medical Center is another excellent alternative for multiple myeloma patients in the Midwest. Since maintenance therapy with lenalidomide has only recently been adopted, UNMC believes their 4 year survival statistics will continue to improve. For a link CLICK HERE.
Eastern Region
Dartmouth Hitchcock Medical Center - Lebanon, NH - They list a 3 year survival of 76.8 %* with auto transplant vs the SEER data of 55.6%. You are 1.9* times more likely to die in 3 years under treatment at the average SEER facility than if treated at Dartmouth. Link: http://med.dartmouth-hitchcock.org/quality/metric_BMT/SURVIVAL_-_Multiple_Myeloma/Multiple_myeloma_-_3_year_survival
Memorial Sloan-Kettering Cancer Center(Sergio Giralt, MD), New York, NY - I am honored to present the most recent data from MSKCC for their 2 year relative survival rate. They have provided their transplant data for all patients who received an autologous transplant either early or late in disease progression. I have hoped to be able to provide more east coast options for the myeloma patient community, and want to sincerely thank Dr. Giralt for going through the effort to consolidate his data. Their two year survival is 88.4% versus the National Cancer Institutes 2 year survival of 64.1%. You are 3.1 times more likely to die in 2 years if treated at the average SEER facility rather than at MSKCC. This is now the best performance for any east cost facility! Link: http://www.mskcc.org/cancer-care/doctor/sergio-giralt
Roswell Park Cancer Institute(Phillip McCarthy MD), Buffalo, NY - Roswell Park lists auto transplant outcomes for Multiple Myeloma. Between 2007-2013, Roswell Park's BMT program performed 112 first auto peripheral blood stem cell transplant. All 112 patients (100 percent) were alive 100 days after transplant, and overall 94 percent were alive one year after transplant. This means Relative Survival was 95.9% vs 80.7% for the average of all National Cancer Institute SEER facilities. You are therefore 4.7 times more likely to die at the average SEER facility than if you were under the care of Dr. McCarthy at Roswell Park. For more information CLICK HERE.
Memorial Sloan-Kettering Cancer Center(Sergio Giralt, MD), New York, NY - I am honored to present the most recent data from MSKCC for their 2 year relative survival rate. They have provided their transplant data for all patients who received an autologous transplant either early or late in disease progression. I have hoped to be able to provide more east coast options for the myeloma patient community, and want to sincerely thank Dr. Giralt for going through the effort to consolidate his data. Their two year survival is 88.4% versus the National Cancer Institutes 2 year survival of 64.1%. You are 3.1 times more likely to die in 2 years if treated at the average SEER facility rather than at MSKCC. This is now the best performance for any east cost facility! Link: http://www.mskcc.org/cancer-care/doctor/sergio-giralt
Roswell Park Cancer Institute(Phillip McCarthy MD), Buffalo, NY - Roswell Park lists auto transplant outcomes for Multiple Myeloma. Between 2007-2013, Roswell Park's BMT program performed 112 first auto peripheral blood stem cell transplant. All 112 patients (100 percent) were alive 100 days after transplant, and overall 94 percent were alive one year after transplant. This means Relative Survival was 95.9% vs 80.7% for the average of all National Cancer Institute SEER facilities. You are therefore 4.7 times more likely to die at the average SEER facility than if you were under the care of Dr. McCarthy at Roswell Park. For more information CLICK HERE.
Europe
No data to date
General International Information
CIBMTR(Center for International Blood and Marrow Transplant Research)Transplant Hospitals - This grouping of 500 hospitals from throughout the world report their transplant data and list the average 2 year survival with auto transplant of approximately 83.9%* vs the SEER data of 65% and a 4 year survival of 69.9%* vs. the SEER data 50.2%. Link : http//www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Pages/index.aspx (Slide 40 of the summary slides) This listing includes Dana Farber, Mayo, Ceder Sinai, UAMS, Weil Cornell, M.D. Anderson and many many more. In that each listed facility has provided this data to CIBMTR, you should be able to obtain their most current auto transplant survival data for multiple myeloma. The link to this listing is at: http://www.cibmtr.org/About/WhoWeAre/Centers/Pages/index.aspx
The Myeloma Beacon provides a listing of Multiple Myeloma Centers by state at the link: http://www.myelomabeacon.com/resources/treatment-centers/ This list is based on reputation which may or many not be a reflection of excellent survival rate performance. Many do however have survival rates listed on this site that are way about average. These include Mayo(Rochester), UAMS(Little Rock), Huntsman, et al, however the list does not include some of the very best centers like Dr. Berenson's IMBCR, which has the best 5 year survival, or Dr. Hari's Medical College of Wisconsin, which has the best 2 and 3 year survival. Please cross reference this list with those that have provided data to this web site. The listing looks very good, however, we do not have data to confirm the reputation for all treatment centers on the list. You may want to use the research tools identified above to find the multiple myeloma specialists at each of the listed facilities.
Hospitals with Studies or Clinical Trials with exceptional survival**
Southern Region
Mayo, Scottsdale, AZ - A multicenter study of CyBorD or treatment plan that consists of Cyclophophamide, Bortezomib, and dex, with a 3 year survival of 88% vs. the SEER data of 55.6%. So you would be 3.7 times more likely to die at the average SEER facility than if you participated in this trial. An estimate for the survival of those that transplanted and those that did not is 95% transplant and 75% for non transplant. The link is as follows: http://www.myelomabeacon.com/news/2011/12/06/initial-treatment-with-cyclophosphamide-velcade-bortezomib-and-dexamethasone-cybord-compares-favorably-in-terms-of-response-rates-and-side-effects/
UAMS(Dr. Bart Barlogie) Little Rock, AR - A study called TT3 of VTD-PACE with dual transplant and maintenance has a 5 year survival or 78% vs. the SEER data of 40.9%. You are 2.7 times more likely to die under the care of the average SEER facility rather than if you participated in this myeloma treatment protocol The specifics of this trial are in the attached article: http://jco.ascopubs.org/content/28/7/1209.full
UAMS(Dr. Bart Barlogie) Little Rock, AR - A study called TT3 of VTD-PACE with dual transplant and maintenance has a 5 year survival or 78% vs. the SEER data of 40.9%. You are 2.7 times more likely to die under the care of the average SEER facility rather than if you participated in this myeloma treatment protocol The specifics of this trial are in the attached article: http://jco.ascopubs.org/content/28/7/1209.full
Western Region
Mayo Clinic(Dr. Mikhael) Scotsdale, AZ - This multicenter study of newly diagnosed patients includes Cylophosphamide, Carfilzomib(Kyprolis), Thalidomide, and Dexamethasone or (CYCLONE), has an overall response rate of 100%, and a CR rate of 35%. The results are too new to show overall survival, but initial results are very promising. The link: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99972
Midwest Region
Mayo Clinic(Dr Rajkumar) Rochester, MN - This multicenter study of Rd, or Revlimid and low dose dex shows a two year survival of 87% vs the SEER data of 65.6% This is with and without transplant. You would be 2.7 times more likely to die in two years if treated at the average SEER facility vs. participation in this trial. The data is in the following presentation: http://myeloma.org/pdfs/ash2007_rajkumare4a03.pdf
University of Chicago( Dr. Jakubowiak) , Chicago, Illinois - A multicenter study of Carfilzomib(Kyprolis), Lenalidomide, and low dose Dexamethasone for newly diagnosed patients. KRd provided a high rate of sCR (55%) in NDMM patients (pts) and 3-year progression-free survival and OS rates of 79% and 96%. Relative survival would therefore be 101.8% vs. the SEER relative survival of 64%. This is a truly remarkable performance in that the 3 year survival is greater than that of the average person at age 69. The study was expanded To further improve response and outcomes, by designed a phase II study to assess activity of extended treatment with KRd induction, ASCT, KRd consolidation, and KRd maintenance. With a medium followup of just 9.7 months the results are not seasoned but still outstanding. Response improved with each phase of treatment and at the end of 8 cycles, 15/17 evaluable patients (88%) were MRD-negative, all patients were alive and 52 of 53 progression free. KRd with ASCT for newly diagnosed patients resulted in higher sCR rates than KRd without ASCT and high rate of MRD-negative disease, suggestive of benefit of adding ASCT to KRd treatment. The study link: http://meetinglibrary.asco.org/content
University of Chicago( Dr. Jakubowiak) , Chicago, Illinois - A multicenter study of Carfilzomib(Kyprolis), Lenalidomide, and low dose Dexamethasone for newly diagnosed patients. KRd provided a high rate of sCR (55%) in NDMM patients (pts) and 3-year progression-free survival and OS rates of 79% and 96%. Relative survival would therefore be 101.8% vs. the SEER relative survival of 64%. This is a truly remarkable performance in that the 3 year survival is greater than that of the average person at age 69. The study was expanded To further improve response and outcomes, by designed a phase II study to assess activity of extended treatment with KRd induction, ASCT, KRd consolidation, and KRd maintenance. With a medium followup of just 9.7 months the results are not seasoned but still outstanding. Response improved with each phase of treatment and at the end of 8 cycles, 15/17 evaluable patients (88%) were MRD-negative, all patients were alive and 52 of 53 progression free. KRd with ASCT for newly diagnosed patients resulted in higher sCR rates than KRd without ASCT and high rate of MRD-negative disease, suggestive of benefit of adding ASCT to KRd treatment. The study link: http://meetinglibrary.asco.org/content
Eastern Region
Princess Margaret Hospital, Toronto, Canada - A study of CyBorD or Cyclophophamide, Bortezomib, and dex, with a 3 year survival of 88% vs. the SEER data of 55.6%. You would be 3.7 times more likely to die in 3 years at the average SEER facility vs. participating in this trial. An estimate for the survival of those that transplanted and those that did not is 95% transplant and 75% for non transplant. The link is as follows: http://www.myelomabeacon.com/news/2011/12/06/initial-treatment-with-cyclophosphamide-velcade-bortezomib-and-dexamethasone-cybord-compares-favorably-in-terms-of-response-rates-and-side-effects/
Dana Farber Cancer Institute(Dr. Ken Anderson & Dr. Paul Richardson), Boston Mass. - A multicenter study of RVD or Revlimid Velcade Dex with and without transplant provides a 18 month survival of 97% for all patients(with and without transplant) vs. an estimate of a SEER value between 1 and 2 years of 71%. You would be almost 10 times more likely to die in 18 months at the average SEER faciltiy than in this trial. The data is available in the following link: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=52410
Weill Cornell(Dr. Ruben Niesvizky) , NY,NY - BiRd or Biaxin, lenalidomide, and low dose dexamethasone had a 3 year survival of 89.7% vs. the SEER data of 55.6%. If part of this multicenter trial you are 4 times more likely to die at the average SEER facility than if you participated in this trail. The data is available in the following link: http://www.ncbi.nlm.nih.gov/pubmed/20645430
Dana Farber Cancer Institute(Dr. Ken Anderson & Dr. Paul Richardson), Boston Mass. - A multicenter study of RVD or Revlimid Velcade Dex with and without transplant provides a 18 month survival of 97% for all patients(with and without transplant) vs. an estimate of a SEER value between 1 and 2 years of 71%. You would be almost 10 times more likely to die in 18 months at the average SEER faciltiy than in this trial. The data is available in the following link: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=52410
Weill Cornell(Dr. Ruben Niesvizky) , NY,NY - BiRd or Biaxin, lenalidomide, and low dose dexamethasone had a 3 year survival of 89.7% vs. the SEER data of 55.6%. If part of this multicenter trial you are 4 times more likely to die at the average SEER facility than if you participated in this trail. The data is available in the following link: http://www.ncbi.nlm.nih.gov/pubmed/20645430
Europe
French Myeloma Intergroup - This multicenter trial of RVD with Transplant, RVD Consolidation, and R Maintenance showed exceptional results for newly diagnosed patients. With a median follow-up of 39 months, estimated 3-year progression-free and overall survival were 77% and 100%. Overall, 58% of patients achieved complete response, and 68% were minimal residual disease (MRD) negative by flow cytometry. The survival of 100% is remarkable in comparison to the SEER data which has a 64% survival rate. Link: http://jco.ascopubs.org/content/early/2014/07/10/JCO.2013.54.8164.abstract
University Hospital ( Dr. Jesús San Miguel) Salamanca, Spain - This multicenter trial of VMP Velcade-melpahalan-Predisone for older transplant ineligible patients provided a 5 year survival of 46% vs. the SEER data of 40.9%. The link is: http://ash.confex.com/ash/2011/webprogram/Paper37551.html
University of Torino(Dr. Antonio Palumbo) Torino, Italy - This muticenter study of VMPT-VT or Velcade-melphalan-predisone-thalidomide with Velcade- thalidomide maintenance shows a 3 year survival of 89% vs. the SEER data of 55.6%. This is with older transplant ineligible patients. If you were in this trial you would be 4 times more likely to die at the average SEER facility than if your participated in this trial. Link: http://jco.ascopubs.org/content/early/2010/10/07/JCO.2010.29.8216.full.pdf Another study with PAD(Bortezomib, doxorubicin, and dex), two transplants, LP consolidation and L maintenance had a two year survival of 86% vs the SEER of 65.6%. Link: http://jco.ascopubs.org/content/28/5/800.full.pdf
*SEER numbers are based on Relative Survival (myeloma deaths only) whereas others are based on Observed Survival(all deaths) and as a result these numbers must be adjusted upward to be comparable to the SEER data. See page 3 for more information on methodology.
**All the drugs in the above trials have been approved for use in multiple myeloma in the USA and do not require clinical trials for use, however they may not be approved in every country.
*This multiple is computed by taking the the death rate of the SEER data (1-.41) and dividing it by the death rate of the hospital listed above(1-.897) or 5.7 times. Another way to look at it is to say of 100 people 59 have died in the SEER facility's in 5 years, while only 10.3 have died in the listed hospital's care. So you are 5.7 times (59/10.3) more likely to die if you were treated in the average SEER facility as compared to the listed facility. This can be confused with a comparison of the survival rates. The survival rates are only different by 2.18 times or 89.7/41, which I believe is less valuable as a measure for the multiple myeloma patient community.
University Hospital ( Dr. Jesús San Miguel) Salamanca, Spain - This multicenter trial of VMP Velcade-melpahalan-Predisone for older transplant ineligible patients provided a 5 year survival of 46% vs. the SEER data of 40.9%. The link is: http://ash.confex.com/ash/2011/webprogram/Paper37551.html
University of Torino(Dr. Antonio Palumbo) Torino, Italy - This muticenter study of VMPT-VT or Velcade-melphalan-predisone-thalidomide with Velcade- thalidomide maintenance shows a 3 year survival of 89% vs. the SEER data of 55.6%. This is with older transplant ineligible patients. If you were in this trial you would be 4 times more likely to die at the average SEER facility than if your participated in this trial. Link: http://jco.ascopubs.org/content/early/2010/10/07/JCO.2010.29.8216.full.pdf Another study with PAD(Bortezomib, doxorubicin, and dex), two transplants, LP consolidation and L maintenance had a two year survival of 86% vs the SEER of 65.6%. Link: http://jco.ascopubs.org/content/28/5/800.full.pdf
*SEER numbers are based on Relative Survival (myeloma deaths only) whereas others are based on Observed Survival(all deaths) and as a result these numbers must be adjusted upward to be comparable to the SEER data. See page 3 for more information on methodology.
**All the drugs in the above trials have been approved for use in multiple myeloma in the USA and do not require clinical trials for use, however they may not be approved in every country.
*This multiple is computed by taking the the death rate of the SEER data (1-.41) and dividing it by the death rate of the hospital listed above(1-.897) or 5.7 times. Another way to look at it is to say of 100 people 59 have died in the SEER facility's in 5 years, while only 10.3 have died in the listed hospital's care. So you are 5.7 times (59/10.3) more likely to die if you were treated in the average SEER facility as compared to the listed facility. This can be confused with a comparison of the survival rates. The survival rates are only different by 2.18 times or 89.7/41, which I believe is less valuable as a measure for the multiple myeloma patient community.
Excellent Multiple Myeloma Resources
|
International Myeloma Foundation(IMF) - http://myeloma.org/Main.action Multiple Myeloma Research Foundation(MMRF) http://www.themmrf.org/ CureTalk(New treatments and clinical trials) - http://trialx.com/curetalk/ Myeloma Crowd = http://www.myelomacrowd.org/ Patient to Patient Support - https://www.smartpatients.com/conversations LLS(The Leukemia & Lymphoma Society) $10,000 Myeloma Co Pay assist - http://www.lls.org/diseaseinformation/getinformationsupport/financialmatters/copayassistance/ |
Managing Myeloma - http://www.managingmyeloma.com/ mPatient - http://www.mpatient.org/ Living with Multiple Myeloma - http://multiplemyelomablog.com/ Cancer Care Copay assist $3500 - http://www.cancercarecopay.org/apply.html Patient Power - Multiple Myeloma - http://www.patientpower.info/multiple-myeloma Nick Van Dyke discusses the highly effective Total Therapy Program of UAMS-MIRT at Little Rock - http://nvdmyeloma.blogspot.com/ Myeloma Beacon - http://www.myelomabeacon.com/ |
©2012 All Rights Reserved, ©, A not for profit organization! But for the benefit of the myeloma patient community!